DNA aptamers selection for carcinoembryonic antigen (CEA)

被引：15

作者：

Abreu de Melo, Mariane Izabella ^{[1
]}

Correa, Cristiane Rodrigues ^{[1
]}

Cunha, Pricila da Silva ^{[1
]}

de Goes, Alfredo Miranda ^{[2
]}

Gomes, Dawidson Assis ^{[2
]}

Ribeiro de Andrade, Antero Silva ^{[1
]}

机构：

[1] Comissao Nacl Energia Nucl, Ctr Desenvolvimento Tecnol Nucl, Av Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil

[2] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, Av Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2020年 / 30卷 / 15期

关键词：

COLON-CANCER CELLS; BREAST-CANCER; RNA APTAMER; LABEL-FREE; APTASENSOR; MOLECULES; DNAZYME;

D O I：

10.1016/j.bmcl.2020.127278

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Carcinoembryonic antigen (CEA) is a glycoprotein antigen generally used for diagnosis, prognosis and treatment monitoring of several types of tumors, including colorectal cancer. Nucleic acid aptamers are DNA or RNA oligonucleotides capable of binding with high specificity and affinity to a molecular target. The aim of this study was to obtain aptamers specific to CEA for use as radiopharmaceuticals in colorectal cancer diagnosis. Five aptamers were selected through the Systematic Evolution of Ligands by EXponencial Enrichment (SELEX) and tested using T84 (CEA+) and Hela (CEA−) cells. Apta 3 and Apta 5 showed the best results presenting high specificity and affinity for T84 cells, with dissociation constants (Kd) of 60.4 ± 5.7 nM and 37.8 ± 5.8 nM, respectively. These results indicate that Apta 3 and Apta 5 are promising candidates for identifying tumor cells that overexpress CEA. © 2020 Elsevier Ltd

引用

页数：6

共 50 条

[21] MAb against carcinoembryonic antigen (CEA)
Yildirim, T
Akfirat, FS
Derebay, E
Sezen, IY
HYBRIDOMA, 2005, 24 (06): : 319 - 320
[22] AFFINITY CHROMATOGRAPHY OF CARCINOEMBRYONIC ANTIGEN (CEA)
TURNER, MD
ALLEN, PZ
FEDERATION PROCEEDINGS, 1974, 33 (03) : 792 - 792
[23] POLYPEPTIDE MOIETY OF CARCINOEMBRYONIC ANTIGEN (CEA)
NEWMAN, ES
PETRAS, SE
GEORGIAD.A
HANSEN, HJ
MILLER, ON
FEDERATION PROCEEDINGS, 1974, 33 (05) : 1562 - 1562
[24] CARCINOEMBRYONIC ANTIGEN (CEA), PROBLEMS AND PERSPECTIVES
NAP, M
BULLETIN DU CANCER, 1986, 73 (03) : 325 - 331
[25] PREPARATION AND ASSAY OF CARCINOEMBRYONIC ANTIGEN (CEA)
MARSHALL, VR
HOFFMANN, DC
CHALMERS, AH
AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1972, 42 (01): : 100 - &
[26] COMPARISON OF CARCINOEMBRYONIC ANTIGEN (CEA) METHODOLOGIES
FLEISHER, M
BESENFELDER, E
OETTGEN, HF
SCHWARTZ, MK
ANNALS OF CLINICAL AND LABORATORY SCIENCE, 1974, 4 (05): : 357 - 362
[27] CARCINOEMBRYONIC ANTIGEN (CEA) IN CLINICAL DIAGNOSIS
EDGINGTO.TS
CALIFORNIA MEDICINE, 1973, 119 (03): : 48 - 48
[28] PROGRESS REPORT CARCINOEMBRYONIC ANTIGEN (CEA)
DYKES, PW
KING, J
GUT, 1972, 13 (12) : 1000 - 1013
[29] CARCINOEMBRYONIC ANTIGEN (CEA) IN LIVER DISEASE
MOORE, TL
KUPCHIK, HZ
DHAR, P
ZAMCHECK, N
GASTROENTEROLOGY, 1971, 60 (04) : 700 - &
[30] STUDIES ON RAT CARCINOEMBRYONIC ANTIGEN (CEA)
WILHELM, S
ABEYOUNIS, CJ
MILGROM, F
FEDERATION PROCEEDINGS, 1982, 41 (03) : 412 - 412

← 1 2 3 4 5 →